• The Outperformers (51-60)

  These companies have been ranked based on their stock's excess return over the Sensex for a five-year period

  September 03, 2019

• The Keymakers

  With a powerful client base and an all-in-one package, the contract R&D firm Syngene is galloping ahead and now even into manufacturing 

  Shruti Venkatesh - May 17, 2019

• Injecting Growth

  By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next

  Jash Kriplani - April 16, 2018

• Is the worst over for pharma stocks?

  The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues 

  July 17, 2017

• Under The Weather- Part 1

  The domestic pharma industry, which is already battling the US FDA, has now to contend with regulatory challenges at home

  Krishna Gopalan - May 20, 2017

• Under The Weather - Part 2

  Even as it battles the US FDA, the industry has been caught off-guard by policy changes back home

  Krishna Gopalan - June 05, 2017

• One giant leap for Mankind

  Mankind Pharma made it big in small towns, but can its magic help it conquer the bigger markets?

  Himanshu Kakkar - January 21, 2016

• Will Sun rise again?

  Can Sun Pharma’s Dilip Shanghvi work his merger magic on Ranbaxy?

  Kripa Mahalingam - June 15, 2015

• Hot wheels

  Nephroplus’ Vikram Vuppala’s eight-wheelers can outrun any fancy car

  Aditi Saxena - June 17, 2015

• "If you believe in something, have the courage to take it to completion"

  The Piramal group head on how his values have helped him make bold business decisions

  N Mahalakshmi - December 21, 2015